A1 Journal article (refereed)
A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates (2020)

Stone, V. M., Hankaniemi, M.M., Laitinen, O. H., Sioofy-Khojine, A. B., Lin, A., Diaz Lozano, I. M., Mazur, M. A., Marjomäki, V., Loré, K., Hyöty, H., Hytönen, V. P., & Flodström-Tullberg, M. (2020). A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Science Advances, 6(19), Article eaaz2433. https://doi.org/10.1126/sciadv.aaz2433

JYU authors or editors

Publication details

All authors or editors: Stone, V. M.; Hankaniemi, M. M.; Laitinen, O. H.; Sioofy-Khojine, A. B.; Lin, A.; Diaz Lozano, I. M.; Mazur, M. A.; Marjomäki, V.; Loré, K.; Hyöty, H.; et al.

Journal or series: Science Advances

eISSN: 2375-2548

Publication year: 2020

Volume: 6

Issue number: 19

Article number: eaaz2433

Publisher: American Association for the Advancement of Science

Publication country: United States

Publication language: English

DOI: https://doi.org/10.1126/sciadv.aaz2433

Publication open access: Openly available

Publication channel open access: Open Access channel

Publication is parallel published (JYX): https://jyx.jyu.fi/handle/123456789/69009

Abstract

Coxsackievirus B (CVB) enteroviruses are common human pathogens known to cause severe diseases including myocarditis, chronic dilated cardiomyopathy, and aseptic meningitis. CVBs are also hypothesized to be a causal factor in type 1 diabetes. Vaccines against CVBs are not currently available, and here we describe the generation and preclinical testing of a novel hexavalent vaccine targeting the six known CVB serotypes. We show that the vaccine has an excellent safety profile in murine models and nonhuman primates and that it induces strong neutralizing antibody responses to the six serotypes in both species without an adjuvant. We also demonstrate that the vaccine provides immunity against acute CVB infections in mice, including CVB infections known to cause virus-induced myocarditis. In addition, it blocks CVB-induced diabetes in a genetically permissive mouse model. Our preclinical proof-of-concept studies demonstrate the successful generation of a promising hexavalent CVB vaccine with high immunogenicity capable of preventing CVB-induced diseases.

Keywords: enteroviruses; vaccines; antibodies; immunity; juvenile diabetes; animal disease models

Contributing organizations

Ministry reporting: Yes

Reporting Year: 2020

JUFO rating: 3